RSS   Newsletter   Contact   Advertise with us
Post Online Media

Charles Gregory Vontz joins BioPharmX board of directors

BioPharmXBioPharmX Corporation, a specialty pharmaceutical company, announced the appointment of Charles Vontz as an independent director.

Mr. Vontz most recently served as president and CEO of Topica Pharmaceuticals, which developed luliconazole for fungal infections of the skin, a product acquired by Medicis Pharmaceutical Corporation.

READ MORE BioPharmX appoints Stephen Morlock to its board

Earlier, Mr. Vontz was president and chief operating officer of Connetics Corporation, a public specialty pharmaceutical company, focusing on dermatology. Connetics was acquired by Stiefel Pharmaceuticals in late 2006.

Before joining Connetics, Mr. Vontz spent 12 years at Genentech in various senior marketing and product development roles.

He got his start in the pharmaceutical industry with Merck, Sharp and Dohme where he worked from 1985-1987 in sales and sales management.

Mr. Vontz is also a member of the board of directors for SinuSys Corporation.

He is a graduate of the University of Florida and received a Masters in Business Administration from the Haas School of Business at the University of California at Berkeley.


 LATEST MOVES FROM California 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy